Upstream Bio (UPB) EPS (Weighted Average and Diluted) (2023 - 2026)
Upstream Bio's quarterly EPS (Weighted Average and Diluted) came in at -$0.75 in Q1 2026, down 47.06% year-on-year from -$1.42 in Q1 2025, and up 3.85% quarter-over-quarter from -$0.78 in Q4 2025.
Upstream Bio has reported EPS (Weighted Average and Diluted) for 4 years, with the latest figure at -$0.75 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) fell 47.06% year-over-year to -$0.75; the trailing twelve-month figure through Mar 2026 stood at -$2.9 (down 107.14% YoY), and the FY2025 full-year result was -$2.66, up 52.33% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.75, up from -$0.78 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $12.57 in Q4 2024, with the low at -$6.96 in Q3 2024.
- Average EPS (Weighted Average and Diluted) over 4 years is -$1.47, with a median of -$0.78 recorded in 2025.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 348.91% in 2024, while the deepest fall reached 229.86% in 2024.
- Tracing UPB's EPS (Weighted Average and Diluted) over 4 years: stood at -$5.05 in 2023, then surged by 348.91% to $12.57 in 2024, then tumbled by 106.21% to -$0.78 in 2025, then advanced by 3.85% to -$0.75 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.75 (Q1 2026), -$0.78 (Q4 2025), and -$0.63 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | -0.75 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.75 |
| Dec 31, 2025 | -0.78 |
| Sep 30, 2025 | -0.63 |
| Jun 30, 2025 | -0.74 |
| Mar 31, 2025 | -0.51 |
| Dec 31, 2024 | 12.57 |
| Sep 30, 2024 | -6.96 |
| Jun 30, 2024 | -6.50 |
| Mar 31, 2024 | -4.68 |
| Dec 31, 2023 | -5.05 |
| Sep 30, 2023 | -2.11 |